Given that nearly every T-PLL case harbors a genomic aberration potentially activating JAK/STAT signaling, JAK and STAT proteins are clinically relevant targets for T-PLL therapy [50]. Here, SOAT1 is linked to T-cell prolymphocytic leukemia.